Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
Go back to Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer| MACROGENICS (NASDAQ: MGNX) | Delayed: 4.14 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.14 | 52 Week High | $36.11 | |||
| Open | $4.14 | 52 Week Low | $14.84 | |||
| Day High | $4.14 | P/E | 10.62 | |||
| Day Low | $4.14 | EPS | $0.39 | |||
| Volume | 4,982 | |||||
| (NASDAQ: ZLAB) | Delayed: 25.70 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.70 | 52 Week High | $ | |||
| Open | $25.70 | 52 Week Low | $ | |||
| Day High | $25.70 | P/E | N/A | |||
| Day Low | $25.70 | EPS | $ | |||
| Volume | 42,468 | |||||

